Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV treatments often include dolutegravir, raltegravir, rilpivirine or cobicistat, which inhibit the proximal tubular secretion of creatinine without impairing kidney function, thus leading to measurement bias when using creatinine-based estimated GFR (eGFR). We developed eGFR correction factors to account for this potential bias.

中文翻译：

---

通过抑制来自普通抗逆转录病毒药物的肌酐肾小管分泌，评估在估计肾小球滤过率 (eGFR) 中引入的偏差。

研究人员必须经常依靠肌酐测量值来评估肾功能，因为在常规临床环境中很少测量直接肾小球滤过率 (GFR) 和胱抑素-c。然而，HIV 治疗通常包括 dolutegravir、raltegravir、rilpivirine 或 cobicistat，它们在不损害肾功能的情况下抑制肌酐的近端肾小管分泌，因此在使用基于肌酐的估计 GFR (eGFR) 时会导致测量偏差。我们开发了 eGFR 校正因子来解释这种潜在的偏差。